Ian Chau

Ian Chau at the Royal Marsden is a leading UK gastric and esophageal cancer specialist who has contributed to the DESTINY-Gastric program evaluating trastuzumab deruxtecan in HER2-positive gastric cancer. His research spans anti-HER2 therapy, immunotherapy, and targeted agents in upper GI malignancies. He has been instrumental in establishing trastuzumab deruxtecan as a second-line option for HER2-positive gastric and GEJ cancer with superior outcomes compared to trastuzumab emtansine. His work on understanding HER2 heterogeneity and its implications for T-DXd response has contributed to precision oncology in gastric cancer.